Currently, there are several biomarkers, such as cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), IL-18, and tissue inhibitor of metalloproteinase 2 (TIMP-2), that may predict AKI and enable the identification of patients with evidence of kidney injury. This evidence concerns the gene LCN2 and kidney injury.